ストックスクリーナーアプリを入手
35.97
1.34%
-0.49
アフターアワーズ：
35.80
-0.17
-0.47%
Bridgebio Pharma Inc (BBIO) 最新ニュース
Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025? - Insider Monkey
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
BBIO (BridgeBio Pharma) Cash Flow for Dividends : $0.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
BBIO (BridgeBio Pharma) EBITDA : $-350.3 Mil (TTM As of Sep. 2024) - GuruFocus.com
Why BridgeBio Pharma (BBIO) Is Skyrocketing Now - MSN
14,302 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Acquired by Atomi Financial Group Inc. - MarketBeat
(BBIO) Trading Report - Stock Traders Daily
Equities Analysts Set Expectations for BBIO FY2025 Earnings - MarketBeat
Research Analysts Issue Forecasts for BBIO FY2025 Earnings - Defense World
Leerink Partnrs Has Negative Estimate for BBIO Q4 Earnings - Defense World
Cantor Fitzgerald Predicts BBIO FY2025 Earnings - MarketBeat
Leerink Partnrs Analysts Reduce Earnings Estimates for BBIO - MarketBeat
BridgeBio’s Neil Kumar on an underdog drug launch and wooing deal-hungry investors - BioPharma Dive
Why Is Andreas Halvorsen Bullish On BridgeBio Pharma, Inc. (BBIO) Now? - Insider Monkey
First Week of March 21st Options Trading For BridgeBio Pharma (BBIO) - Nasdaq
Top 4 Health Care Stocks You May Want To Dump In Q1 - Benzinga
Moss Adams Wealth Advisors LLC Acquires New Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Up 12.7% in December - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 6.6%Time to Buy? - MarketBeat
Hypoparathyroidism Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart
Hypoparathyroidism Market Anticipated to Expand Rapidly - openPR
Is BridgeBio Pharma, Inc. (BBIO) Among Tuesday’s Top Gainers? - MSN
Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength? - MSN
BridgeBio Pharma Is A Buy On Dips After Attruby’s FDA Approval (NASDAQ:BBIO) - Seeking Alpha
Why BridgeBio Pharma (BBIO) Led the Monday Upsurge? - MSN
Epidermolysis Bullosa Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Key Companies Involved by DelveInsight | RegeneRx Biopharma, BridgeBio Pharma, Berg Pharma, Holostem Terapie - The Globe and Mail
BridgeBio Pharma Stock Earns 87 RS Rating - Yahoo! Voices
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 6.6%What's Next? - MarketBeat
BridgeBio reports strong Attruby launch, advances phase 3 trials By Investing.com - Investing.com Australia
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. - MSN
BridgeBio Pharma Reports Strong Drug Uptake and Trial Progress - TipRanks
BridgeBio Pharma (NASDAQ:BBIO) Sees Large Volume IncreaseHere's Why - MarketBeat
Investors Purchase High Volume of BridgeBio Pharma Call Options (NASDAQ:BBIO) - MarketBeat
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones - Yahoo Finance
BridgeBio trades higher on pipeline progress By Investing.com - Investing.com Nigeria
BridgeBio Pharma in Strong Cash Position to Launch Attruby -January 13, 2025 at 12:02 pm EST - Marketscreener.com
BridgeBio trades higher on pipeline progress - Investing.com
BridgeBio Pharma in Strong Cash Position to Launch Attruby - MarketWatch
BridgeBio reports strong Attruby launch, advances phase 3 trials - Investing.com
BridgeBio's Attruby Gains Momentum with 430 Prescriptions as Three Phase 3 Trials Hit Key Milestone - StockTitan
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing - Simply Wall St
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):